off
MS buys right to acquire Promedior in $1.25bn deal
The decision to buy the rights to Promedior rather than buying the company out-right is similar to a deal penned past year with Galecto Biotech which is developing an inhaled inhibitor of galectin-3, also in the fibrosis space.
Posted On Sep 01 2015
